Our portfolio company, Total Scientific (TSL) has moved into enlarged accommodation in the newly opened Maia building on the Babraham Research Campus, just south of Cambridge, UK. The new accommodation has been custom-designed to support cell culture as well as a wide range of in vitro biology needs, including TSL's Luminex platform. A suite of offices complement the expanded lab accommodation.

Commenting on the move at a lunch held to mark the expansion, David Mosedale, CEO at TSL, said "We are delighted to be able to stay on the Babraham campus, while at the same time expanding significantly our capacity to support our growing customer base. The state-of-the-art new labs match our core values of quality and excellence."

TSL now has 8 employees, with sales forecast to grow by at least 20% in 2010 despite challenging global economic conditions. The company specialises in provision of biomarker services to diagnostics and drug development companies, including assay design and validation, bioanalysis, bespoke clinical trials, biobanking and data analysis services.

unxional Therapeutics (FXT) have raised a further €10M in a series B round, with new investor Ventech joining existing investors Index Ventures and Novo A/S.

FXT is developing a series of novel anti-inflammatory agents which block chemokine-induced leukocyte migration, with am initial focus on respiratory diseases. Their lead compound, FX125L, successfully completed Phase I earlier in 2010. The new funds will be used to support the further clinical development of this compound.

Karl Naegler has joined the Funxional Therapeutics Board, representing Ventech.

Download the full press release...